Condition (MeSH)
Alveolitis, Extrinsic Allergic
ClinicalTrials.gov lists 35 trials for Alveolitis, Extrinsic Allergic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
34 of the 35 trials are tagged with Alveolitis, Extrinsic Allergic itself; the rest are tagged with a narrower condition beneath it.
When did Alveolitis, Extrinsic Allergic trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 8 |
| 2021 | 5 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 2 |
| 2016 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Alveolitis, Extrinsic Allergic trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 3 |
| Not applicable | 9 |
| Observational | 16 |
How many Alveolitis, Extrinsic Allergic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 5 |
| Completed | 11 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Alveolitis, Extrinsic Allergic trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Avalyn Pharma Inc. | 1 |
| Grupo Medifarma, S. A. de C. V. | 1 |
Which drugs are being tested for Alveolitis, Extrinsic Allergic? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PREDNISOLONE | 3 |
| Benzonatate 200 mg | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pirfenidoneone | 2 |
| BLOOD SAMPLE | 2 |
| Additional blood sample | 1 |
| Hyperpolarized Xe129 | 1 |
| Standard Care | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Alveolitis, Extrinsic Allergic? (37)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Rituximab therapy in patients with treatment-refractory hypersensitivity pneumonitis. | Scientific reports | 2025 | Yes |
| A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis. | BMC pulmonary medicine | 2024 | Yes |
| Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand. | Respirology (Carlton, Vic.) | 2024 | Yes |
| Predictors of pulmonary hypertension in patients with hypersensitivity pneumonitis. | BMC pulmonary medicine | 2023 | Yes |
| Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. | Thorax | 2023 | Yes |
Showing 5 of 37 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hypersensitivity pneumonitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Hypersensitivity pneumonitis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Hypersensitivity pneumonitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hypersensitivity pneumonitis | 31740 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hypersensitivity pneumonitis | 31740 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials.